trial · primary record
DMR-001
Myeloproliferative Neoplasms (MPNs)
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 250 |
| Primary completion | 2030-06 |
| Primary endpoint | To evaluate the safety and tolerability of DMR-001 & determine the MTD, RDE(s), and/or recommended Phase 2 dose(s) in participants with CALR-mutant MPNs, when administered as monotherapy or in combination with ruxolitinib |
| Registry ID | NCT07849231 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:17.473Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07849231
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.